<?xml version="1.0"?>
<?xml-stylesheet type="text/css" href="http://www.feuxdelamour.com/v4/skins/common/feed.css?303"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="fr">
		<id>http://www.feuxdelamour.com/v4/index.php?action=history&amp;feed=atom&amp;title=The_Background_Linked_To_R428</id>
		<title>The Background Linked To R428 - Historique des versions</title>
		<link rel="self" type="application/atom+xml" href="http://www.feuxdelamour.com/v4/index.php?action=history&amp;feed=atom&amp;title=The_Background_Linked_To_R428"/>
		<link rel="alternate" type="text/html" href="http://www.feuxdelamour.com/v4/index.php?title=The_Background_Linked_To_R428&amp;action=history"/>
		<updated>2026-07-02T23:31:19Z</updated>
		<subtitle>Historique pour cette page sur le wiki</subtitle>
		<generator>MediaWiki 1.20alpha</generator>

	<entry>
		<id>http://www.feuxdelamour.com/v4/index.php?title=The_Background_Linked_To_R428&amp;diff=63913&amp;oldid=prev</id>
		<title>Angle3oil : Page créée avec « The dataset is split randomly into training (70%) and testing (30%) sets, and three Cox models are fitted to the training data: (a) a model with only selected clinical cov... »</title>
		<link rel="alternate" type="text/html" href="http://www.feuxdelamour.com/v4/index.php?title=The_Background_Linked_To_R428&amp;diff=63913&amp;oldid=prev"/>
				<updated>2017-02-01T19:31:50Z</updated>
		
		<summary type="html">&lt;p&gt;Page créée avec « The dataset is split randomly into training (70%) and testing (30%) sets, and three Cox models are fitted to the training data: (a) a model with only selected clinical cov... »&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Nouvelle page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;The dataset is split randomly into training (70%) and testing (30%) sets, and three Cox models are fitted to the training data: (a) a model with only selected clinical covariates, (b) a model with only anti-profile scores, and (c) a model with both clinical covariates and the anti-profile scores. For each model, the mean survival at time t is calculated for training set patients surviving and not-surviving at that [http://www.selleckchem.com/products/jq1.html Epigenetic Reader Domain inhibitor] time point. For each patient in the testing set, the predicted survival probability at time t is compared to the surviving group mean and not-surviving group mean, and the closest group is chosen to predict whether the patient will survive or not. These predictions are compared to [https://en.wikipedia.org/wiki/E-64 E-64] actual survival to calculate an accuracy rate (patients censored by the time t are not used for the calculation). This process is repeated for a 100 training and testing subsets created from the main dataset, and the distribution of accuracy values was plotted. For the second breast cancer dataset,31 a Cox model fitted with the pathological stage proved to be less accurate than a model fitted with the anti-profile score (Fig. 5A) for predicting patient death at 5 years. The mean accuracy level for the model fitted with the pathological stage was 0.619, for a model fitted with the anti-profile score was 0.726, and for a model fitted with both covariates was 0.655. A Wilcoxon test between the results from the first and third models yielded P-value [http://www.selleckchem.com/products/r428.html R428 mouse] Anti-profiles applied to Cox proportional hazard models for survival prediction: Cox proportional hazard models with significant clinical covariates and anti-profiles were used to predict patient survival at 5 years for the second breast caner dataset ... We used a similar experiment on the lung and colon-cancer datasets mentioned above, but found that adding anti-profile scores to survival models, including significant clinical covariates, did not improve their performance significantly (Supplementary Fig. 12). Conclusions Our aim has been to develop a robust and stable approach for classification of tumor samples. We have demonstrated that the anti-profile scoring method, which was initially applied for classification between tumor and normal samples, can be extended to classification between tumor samples as well.&lt;/div&gt;</summary>
		<author><name>Angle3oil</name></author>	</entry>

	</feed>